top of page


Stem cells and inflammation


During injuries and inflammation in the central nervous system neural stem/progenitor cells are activated to migrate into the injury. A limited replacement of the injured tissue can be achieved by differentiation of the progenitor cells. The replacement of oligodendrocytes which occurs in the early phases of multiple sclerosis is an example of this mechanism.

Our group works to identify mechanisms important for the regeneration from progenitor cells and how these mechanisms are affected by inflammatory mediators. We have demonstrated that some components in the inflammatory cascade such as nitric oxide can change the fate of the progenitor cells and hampers neurogenesis. We have also demonstrated that progenitor cells carry receptors which on stimulation can cause the release of proinflammatory cytokines from these cells. The aim of our research is to improve the restoration and limit the injury by preservation of restorative mechanisms in the CNS. Our research group consists of neurologists, neurosurgeons and neurobiologists.


Selected publications

Yeung M, Zdunek S, Bergmann O, Bernard S, Salehpour M, Alkass K, et al. Dynamics of oligodendrocyte generation and myelination in the human brain. Cell. 2014 Nov;159(4):766-74.

Pérez Estrada C, Covacu R, Sankavaram S, Svensson M, Brundin L. Oxidative stress increases neurogenesis and oligodendrogenesis in adult neural progenitor cells. Stem Cells Dev. 2014 Oct;23(19):2311-27.

Bergsland M, Covacu R, Perez Estrada C, Svensson M, Brundin L. Nitric oxide-induced neuronal to glial lineage fate-change depends on NRSF/REST function in neural progenitor cells. Stem Cells. 2014 Sep;32(9):2539-49.

Covacu R, Perez Estrada C, Arvidsson L, Svensson M, Brundin L. Change of fate commitment in adult neural progenitor cells subjected to chronic inflammation. J. Neurosci. 2014 Aug;34(35):11571-82.

Confavreux C, O'Connor P, Comi G, Freedman M, Miller A, Olsson T, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Mar;13(3):247-56.

bottom of page